4//SEC Filing
Evans John M. 4
Accession 0000950170-24-039319
CIK 0001745999other
Filed
Mar 31, 8:00 PM ET
Accepted
Apr 1, 4:10 PM ET
Size
7.9 KB
Accession
0000950170-24-039319
Insider Transaction Report
Form 4
Evans John M.
DirectorCEO
Transactions
- Sale
Common Stock
2024-03-28$33.86/sh−60,000$2,031,402→ 998,262 total - Award
Common Stock
2024-03-31+77,500→ 1,076,445 total
Holdings
- 103,000(indirect: By Trust)
Common Stock
Footnotes (4)
- [F1]These shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 29, 2023.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $33.374 to $34.15, inclusive. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F3]Represents restricted stock units ("RSUs") granted to the Reporting Person under the BEAM 2019 Equity Incentive Plan (the "Plan"). Each RSU represents the contingent right to receive one share of BEAM's common stock. The RSUs vest in four substantially equal installments on each of the first four anniversaries of the date of grant, subject to the Reporting Person's continued service with BEAM through each vesting date.
- [F4]Includes 683 shares acquired by the Reporting Person under the BEAM Amended and Restated 2019 Employee Stock Purchase Plan on March 31, 2024.
Documents
Issuer
Beam Therapeutics Inc.
CIK 0001745999
Entity typeother
Related Parties
1- filerCIK 0001786304
Filing Metadata
- Form type
- 4
- Filed
- Mar 31, 8:00 PM ET
- Accepted
- Apr 1, 4:10 PM ET
- Size
- 7.9 KB